載入中
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
前收盤價
US$1.06
−US$0.14 · -11.67%
盤中時間採用ET。市場資料可能有所延遲。
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
日內區間
目前US$1.06
52週區間
目前US$1.06
盤中時間採用ET。市場資料可能有所延遲。
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
日內區間
目前US$1.06
52週區間
目前US$1.06
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 17萬 USD | 100萬 USD | — | — | — |
| 銷貨成本 | 14.6萬 USD | — | — | — | — |
| 毛利 | 2.4萬 USD | 100萬 USD | — | — | — |
| 研究與開發 | 794.9萬 USD | 1133.4萬 USD | 1273.4萬 USD | 4346萬 USD | 1757.6萬 USD |
| 銷售、一般及管理費用 | 1043萬 USD | 1207.5萬 USD | 1297.4萬 USD | 1414.1萬 USD | 1147.4萬 USD |
| 營業費用 | 1823.3萬 USD | 2340.9萬 USD | 2570.8萬 USD | 5760.1萬 USD | 2905萬 USD |
| 利息收入 | 80.6萬 USD | 188.3萬 USD | 272.4萬 USD | 105.2萬 USD | 15.1萬 USD |
| 折舊和攤銷 | 14.6萬 USD | 17.4萬 USD | 18.9萬 USD | 6.9萬 USD | 5.5萬 USD |
| 營業利益 | −1820.9萬 USD | −2240.9萬 USD | −2570.8萬 USD | −5760.1萬 USD | −2905萬 USD |
| 淨利 | −1658.6萬 USD | −1998.5萬 USD | −2084萬 USD | −5422.5萬 USD | −2746.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
年度分割調整後的每股現金分配。
US$0.31
2013年（完整年度）+24.0% 自從 2011
US$0.25
2,011
US$0.31
2,013
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2013年10月28日 | US$0.0021Special | — | — |
股息 | 2011年4月4日 | US$0.0002Special | — | — |
除息 2013年10月28日
US$0.0021
Special
除息 2011年4月4日
US$0.0002
Special
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI28.51萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF11.99萬0.00%954億 USD0.05%US$235+0.80%
Dimensional - US Sustainability Core 1 ETFDFSU1200.00%23.92億 USD0.15%US$48.11+0.48%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR9.60.00%455.91億 USD0.17%US$84.44+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
